News
News
Current position:News > News
News
Securing Market Share in the IL-17 Era: First Movers vs Fast Followers
As IL-17 continues to solidify its role in immunology and autoimmune disease treatment, the therapeutic landscape is evolving rapidly. From the intricacies of cytokine signaling to market dynamics shaped by innovation, pricing, and strategic positioning, understanding the competitive landscape is essential.
2025-08-01
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
CD276 Heats Up: The Race for the Next Blockbuster ADC
2025-07-17
PD-1/VEGF: Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
2025-07-10
IL-11:AbbVie to Acquire Capstan Therapeutics,Further Strengthening Commitment to Transforming Patient Care in Immunology
2025-07-03
What’s Next After GLP-1? ActRII Ignites a New Wave of High-Quality Weight Loss
2025-07-01
TROP2:Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-25
After the GLP-1, where is the next breakthrough in weight-loss drugs?
With global GLP-1 drug sales exceeding $50B in 2024, the weight-loss drug market is evolving fast — but the future goes far beyond single-target therapies.

From GLP-1 multi-target combinations to emerging mechanisms like amylin, ACSL5, and ActRII, the next generation of treatments is shifting toward metabolic optimization, muscle preservation, and sustainable weight loss.
2025-06-19
First 1 2 3 4 Last
Total 4 Page
Jump
Current position:News > News
classify
News
Securing Market Share in the IL-17 Era: First Movers vs Fast Followers
As IL-17 continues to solidify its role in immunology and autoimmune disease treatment, the therapeutic landscape is evolving rapidly. From the intricacies of cytokine signaling to market dynamics shaped by innovation, pricing, and strategic positioning, understanding the competitive landscape is essential.
2025-08-01
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
CD276 Heats Up: The Race for the Next Blockbuster ADC
2025-07-17
PD-1/VEGF: Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports
2025-07-10
IL-11:AbbVie to Acquire Capstan Therapeutics,Further Strengthening Commitment to Transforming Patient Care in Immunology
2025-07-03
What’s Next After GLP-1? ActRII Ignites a New Wave of High-Quality Weight Loss
2025-07-01
TROP2:Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
2025-06-25
After the GLP-1, where is the next breakthrough in weight-loss drugs?
With global GLP-1 drug sales exceeding $50B in 2024, the weight-loss drug market is evolving fast — but the future goes far beyond single-target therapies.

From GLP-1 multi-target combinations to emerging mechanisms like amylin, ACSL5, and ActRII, the next generation of treatments is shifting toward metabolic optimization, muscle preservation, and sustainable weight loss.
2025-06-19
MORE
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit